Introduction to Market Access for Pharmaceuticals -

Introduction to Market Access for Pharmaceuticals

Mondher Toumi (Herausgeber)

Buch | Softcover
204 Seiten
2017
CRC Press (Verlag)
978-1-138-03218-7 (ISBN)
143,40 inkl. MwSt
Market access is the fourth hurdle in the drug development process and the primary driver for global income of any new drug. Without a strategy in place for pricing, showing value for effectiveness and an understanding of the target purchasers’ needs, the drug will fail to reach its intended market value. Introduction to Market Access for Pharmaceuticals is based on an accredited course in this area, taken from the European Market Access University Diploma (EMAUD), and is affiliated with Aix Marseille University.

Key Features:

The first guide to market access for pharmaceuticals based on tested teaching materials
Addresses both pharmaceutical and vaccine products
Includes case studies and scenarios
Covers market access consdierations for Western Europe, the USA, Japan and China
Explains the impact the changing healthcare market will have on your product

Mondher Toumi is M.D. by training, M.Sc. in Biostatistics, and in Biological Sciences (option pharmacology) and Ph.D. in Economic Sciences. Mondher Toumi is Professor of Public Health at Aix-Marseille University. After working for 12 years as Research Manager in the department of pharmacology at the University of Marseille, he joined the Public Health Department in 1993. In 1995 he embraces a carrier in the pharmaceutical industry for 13 years. Toumi was appointed Global Vice President at Lundbeck A/S in charge of health economics, outcome research, pricing, market access, epidemiology, risk management, governmental affairs and competitive intelligence. In 2008, he founded Creativ-Ceutical, an international consulting firm dedicated to support health industries and authorities in strategic decision-making. In February 2009 he was appointed Professor at Lyon I University in the Department of Decision Sciences and Health Policies. The same year, he was appointed Director of the Chair of Public Health and Market Access. He launched the first European University Diploma of Market Access (EMAUD) an international course already followed by almost 350 students. Additionally, he recently created the Market Access Society to promote education, research and scientific activities at the interface of market access, HTA, public health and health economic assessment. He is editor in Chief of the Journal of Market Access and Health Policy (JMAHP) which was just granted PubMed indexation. Toumi is also visiting Professor at Beijing University (Third Hospital). He is a recognized expert in health economics and an authority on market access and risk management. He has more than 250 scientific publications and communications, and has contributed to several books.

Chapter 1: Health as a Good

Chapter 2: Decision-Making in Public Health

Chapter 3: Definition and Concepts

Chapter 4: HTA Decision Analysis framework

Chapter 5: Early HTA Advice

Chapter 6: Overview of Market Access Agreements

Chapter 7: External Reference Pricing

Chapter 8: Gap between Payers and Regulators

Chapter 9: Early Access Programs

Chapter 10: Market Access of Orphan Drugs

Chapter 11: Market Access of Vaccines in Developed Countries

Chapter 12: France

Chapter 13: Germany

Chapter 14: Italy

Chapter 15: Spain

Chapter 16: Sweden

Chapter 17: United Kingdom

Chapter 18: The United States

Chapter 19: Japan

Chapter 20: China

Erscheinungsdatum
Zusatzinfo 40 Tables, black and white; 25 Illustrations, black and white
Verlagsort London
Sprache englisch
Maße 210 x 280 mm
Gewicht 476 g
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Pharmakologie / Pharmakotherapie
Medizin / Pharmazie Pharmazie
Naturwissenschaften Chemie
Technik
Wirtschaft Betriebswirtschaft / Management Marketing / Vertrieb
ISBN-10 1-138-03218-2 / 1138032182
ISBN-13 978-1-138-03218-7 / 9781138032187
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich